Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector ProductionBusiness Wire • 04/26/23
Q1 Earnings Scorecard and Fresh Analyst Reports for Bristol-Myers, Medtronic & Altria GroupZacks Investment Research • 04/25/23
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer PatientsBusiness Wire • 04/20/23
Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple MyelomaBusiness Wire • 04/17/23
Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic DevelopmentBusiness Wire • 04/11/23
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior TherapyBusiness Wire • 03/31/23